-
Keenova Announces New Manuscript on Plantar Fibromatosis Treatment Patterns in Peer-Reviewed Journal of Foot and Ankle Surgery
-
Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition
-
Keenova presents Dupuytren's contracture survey at hand surgery meeting
-
Keenova Announces New Dupuytren's Contracture Survey Presentation About Patient Perceptions and Treatment Outcomes
-
Mallinckrodt Reports Third Quarter 2025 Financial Results
-
Mallinckrodt completes Par Health spin-off, rebrands as Keenova Therapeutics
-
Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics
-
Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance
-
Mallinckrodt completes merger with Endo to form combined therapeutics company
-
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
-
Mallinckrodt (MNK) and Endo (NDOI) Announce Planned Leadership Team for Merged Company
-
Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
-
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
-
Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance
-
Mallinckrodt (MNK) and Endo (NDOI) to Combine
-
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
-
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
-
Exclusive: Mallinckrodt explores sale of generic drugs business - sources
-
Mallinckrodt to pay $100 million to settle U.S. probe on drug pricing
-
Pharma, biotech shares soar as Trump win calms pricing talk
-
Drug Stocks on Watch as Bipartisian Bill Expected on Capping Price Increases
-
Mylan (MYL), Valeant (VRX), Related Stocks Pressured Following Market Open
-
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
-
Guggenheim Defends Mallinckrodt (MNK)
-
Mallinckrodt plc Board Adds $500 Million To Company's Existing Share Repurchase Program
-
Mallinckrodt Pharmaceuticals Receives FDA Clearance For INOmax DS(IR)® Plus MRI Device
-
Stressed Mallinckrodt (MNK) SOTP Suggests $70-$90/Share, Jefferies Says
-
Mallinckrodt's INOmax® Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery
-
Valeant's looming M&A hiatus deals blow to investment banks
-
Mizuho Weighs in on Panic in Specialty Pharmaceuticals Sector (VRX) (AGN) (ENDP) (SCMP) (JAZZ) (MNK)
-
Mallinckrodt plc Provides Business Update Including Fiscal Year 2016 Financial Guidance Excluding Contrast Media and Delivery Systems (CMDS) and Ex-CMDS Historical Financial Information
-
Mallinckrodt Completes Acquisition Of Therakos, Inc.
-
Mallinckrodt Launches Notes Offering
-
Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Acquisition Of Therakos, Inc.
-
Mallinckrodt plc Reports Fiscal 2015 Third Quarter Financial Results
-
Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million
-
Mallinckrodt plc Reports Fiscal 2015 Second Quarter Financial Results; Raises Full Year 2015 Guidance
-
Mallinckrodt Completes Acquisition Of Ikaria
-
Mallinckrodt Launches Notes Offering
-
Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition
-
UPDATE: UBS Upgrades Mallinckrodt (MNK) to Buy
-
Mallinckrodt plc (MNK) Target Lifted to $77 at Jefferies

